Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.
|Number of pages||1|
|Journal||American Journal of Respiratory and Critical Care Medicine|
|Early online date||19 May 2021|
|Publication status||Published - 2021|
|Event||ATS International Conference Committee: ATS 2021 - Virtual event |
Duration: 14 May 2021 → 19 May 2021